Rounded with #Prevention fellow - nice to be sent a great review in @JACCJournals on Therapies in #Diabetes by @NYUCVDPrevent colleagues @JDNewmanMDMPH and Dr Schwartzbard and #Cardiology fellow Dr Wilcox https://t.co/XlhRt01xZh
RT @SemergenGTDM: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of…
RT @SemergenGTDM: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of…
RT @SemergenGTDM: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of…
RT @SemergenGTDM: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of…
RT @SemergenGTDM: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of…
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of Cardiology https://t.co/kX9o5XaN31
RT @edi0029: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar https://t.co/V7LuCtQ9AW htt…
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar https://t.co/V7LuCtQ9AW https://t.co/u5NHyaAZ4N
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
RT @smexcardiologia: En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos c…
Individualizar es la clave, pero definitivamente los GLP1 de aplicación semanal han revolucionado el apego al tratamiento por nuestros pacientes. #SocMexCardio
En diabetes y enfermedad cardiovascular, Que estrategia Farmacológica es la mejor para mi paciente? Existen fármacos con beneficios especiales de acuerdo al contexto de nuestros pacientes. https://t.co/8Z78LEKeSv #SocMexCardio @rodrigogopar @mitrehit @Lui
Another good overview: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists https://t.co/kf9v9W1j0b
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists https://t.co/Bc45SnvkI5
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
【総説】糖尿病薬、メトホルミンからSGLT2阻害薬およびGLP1受容体作動薬まで https://t.co/LHMrZCeQzW
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of Cardiology https://t.co/UW0TEpZ9QC
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @smexcardiologia: En el último número de @JACCJournals , se presenta una revisión histórica del tratamiento para DM. https://t.co/AzTbQi…
RT @smexcardiologia: En el último número de @JACCJournals , se presenta una revisión histórica del tratamiento para DM. https://t.co/AzTbQi…
RT @smexcardiologia: En el último número de @JACCJournals , se presenta una revisión histórica del tratamiento para DM. https://t.co/AzTbQi…
RT @smexcardiologia: En el último número de @JACCJournals , se presenta una revisión histórica del tratamiento para DM. https://t.co/AzTbQi…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @smexcardiologia: En el último número de @JACCJournals , se presenta una revisión histórica del tratamiento para DM. https://t.co/AzTbQi…
RT @smexcardiologia: En el último número de @JACCJournals , se presenta una revisión histórica del tratamiento para DM. https://t.co/AzTbQi…
En el último número de @JACCJournals , se presenta una revisión histórica del tratamiento para DM. https://t.co/AzTbQirl9L #SocMexCardio @AmadaAlvarez @CarlosguizarS @drgianma @Julio_Farjat @jpsanchezluna @jcdelafuentem @rodrigogopar @mitrehit @LuisBaeza1
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
@NYUCVDPrevent @NYUCVRC
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes…
Pharmacologic agents are an important tool in the arsenal for patients with #diabetes, but they also impact #CVD outcomes. Here’s what you need to know: https://t.co/gdY3JAwQDd #JACC @JDNewmanMD https://t.co/rlGdWrJ0CD
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
RT @JACCJournals: In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and thei…
In a new #JACC focus seminar, @JDNewmanMD et al. review diabetic agents such as metformin and #SGLT2 inhibitors, and their effect on #CVD outcomes. https://t.co/gdY3JAwQDd #diabetes https://t.co/FnHLlfzg0p
"Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists" (JACC 2020) - "These medications are becoming essential tools for cardioprotection for patients with diabetes and CVD" - https://t.co/mQ1h2DS7Tz https://t.co/iHQc7EbID8
RT @ValleAlfonso: ▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR
RT @ValleAlfonso: ▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR
Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists | JACC: Journal of the American College of Cardiology https://t.co/UW0TEpZ9QC
RT @ValleAlfonso: ▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR
PODCAST: Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists https://t.co/l24s7NABoj
RT @ValleAlfonso: ▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR
RT @ValleAlfonso: ▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR
RT @ValleAlfonso: ▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR
RT @ValleAlfonso: ▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR
▶️https://t.co/cxj6Igfoc7 via @JACCJournals FOCUS SEMINAR